|
Market Closed -
Hong Kong S.E.
11:08:16 16/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 8.880 HKD | +0.17% |
|
-4.36% | +5.34% |
| 10-15 | CSPC Pharma Gets China Nod for Tumor Drug Trial | MT |
| 10-15 | CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval For SYS6088 Injection In China | CI |
| Market Cap | 101B 12.92B 11.48B 10.64B 9.68B 18.27B 1,226B 18.57B 128B 50.16B 640B 48.48B 47.45B 2,039B | P/E 2026 * |
10x | P/E 2027 * | 14.7x |
|---|---|---|---|---|---|
| Enterprise Value | 90.16B 11.49B 10.21B 9.47B 8.61B 16.25B 1,090B 16.51B 114B 44.61B 569B 43.12B 42.2B 1,814B | EV / Sales 2026 * |
2.34x | EV / Sales 2027 * | 2.44x |
| Free-Float |
67.42% | Yield 2026 * |
5.18% | Yield 2027 * | 4.15% |
| Markets | Quality | ||
|---|---|---|---|
Hong Kong S.E.
| 1093 | Delayed | |
OTC Markets
| CHJTF | Delayed | |
|
Tradegate
| CVG | Real-time | |
|
Boerse Muenchen
| CVG | Real-time | |
|
Deutsche Boerse AG
| CVG | Delayed | |
|
Börse Stuttgart
| CVG | Delayed |
| 1 day | +0.17% | ||
| 1 week | -4.36% | ||
| Current month | -11.82% | ||
| 1 month | +2.07% | ||
| 3 months | +5.34% | ||
| 6 months | -5.93% | ||
| Current year | +5.34% |
| 1 week | 8.72 |  | 9.35 |
| 1 month | 8.62 | | 10.16 |
| Current year | 6.53 | | 10.96 |
| 1 year | 6.53 | | 10.96 |
| 3 years | 4.27 | | 11.63 |
| 5 years | 4.27 | | 11.63 |
| 10 years | 3.87 | | 13.93 |
| Manager | Title | Age | Since |
|---|---|---|---|
George Cai
CEO | Chief Executive Officer | 46 | 19/12/2025 |
Qing Jie Wei
COO | Chief Operating Officer | 56 | 19/12/2025 |
Zhi Yong Qu
PRN | Corporate Officer/Principal | 44 | 01/07/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Dong Chen Cai
CHM | Chairman | 72 | 26/08/2011 |
Zhen Guo Wang
BRD | Director/Board Member | 56 | 20/01/2012 |
Bo Wang
BRD | Director/Board Member | 66 | 21/12/2012 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 6/23/26 A | Other | Director | -700,000 | 0.0061% | ||
| 5/29/26 A | Other | Chairman | 9,402,000 | 0.0816% | ||
| 5/28/26 A | Other | Chairman | 40,000,000 | 0.3471% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.17% | -4.36% | -2.42% | +55.79% | 12.9B | |
| +0.30% | +6.25% | +52.92% | +103.20% | 1,116B | |
| +0.85% | -2.31% | +32.94% | +62.13% | 610B | |
| +0.81% | +3.29% | +25.88% | +93.97% | 501B | |
| +0.76% | +0.58% | +74.50% | +40.62% | 358B | |
| -0.13% | +5.98% | +32.91% | +50.39% | 366B | |
| -0.95% | +4.70% | +19.51% | +43.00% | 288B | |
| -1.98% | +3.73% | -0.86% | +13.43% | 261B | |
| -0.26% | +4.33% | +46.32% | +50.87% | 235B | |
| -0.88% | +3.16% | +32.32% | +96.90% | 195B | |
| Average | -0.20% | +4.29% | +31.40% | +61.03% | 394.27B | |
| Weighted average by Cap. | +0.06% | +4.90% | +38.90% | +71.16% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 38.48B 4.9B 4.36B 4.04B 3.68B 6.94B 465B 7.05B 48.56B 19.04B 243B 18.4B 18.01B 774B | 35.69B 4.55B 4.04B 3.75B 3.41B 6.43B 432B 6.54B 45.04B 17.66B 225B 17.07B 16.7B 718B |
| Net income | 10.14B 1.29B 1.15B 1.06B 969M 1.83B 123B 1.86B 12.8B 5.02B 64.01B 4.85B 4.75B 204B | 7.02B 894M 795M 737M 670M 1.27B 84.88B 1.29B 8.86B 3.47B 44.29B 3.36B 3.28B 141B |
| Net Debt | -11.22B -1.43B -1.27B -1.18B -1.07B -2.02B -136B -2.05B -14.15B -5.55B -70.79B -5.36B -5.25B -226B | -14.29B -1.82B -1.62B -1.5B -1.36B -2.57B -173B -2.62B -18.03B -7.07B -90.15B -6.83B -6.69B -287B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/10/26 | HK$8.880 | +0.17% | 72,899,598 |
| 15/10/26 | HK$8.865 | +0.62% | 64,018,514 |
| 14/10/26 | HK$8.810 | -2.81% | 63,588,814 |
| 13/10/26 | HK$9.065 | +0.44% | 44,916,142 |
| 12/10/26 | HK$9.025 | -0.66% | 59,127,086 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 1093 Stock
Select your edition
All financial news and data tailored to specific country editions
